Baidu
map

Oncogene:AML潜在的治疗策略 — 以自噬或ATF4为治疗标靶。

2017-10-31 fengxiangxin MedSci原创

FLT3酪氨酸激酶受体中的内部串联重复突变(FLT3-ITD),在急性髓性白血病(AML)中的发生率约为25%,并且与不良预后相关。为了更好地针对此类AML亚型,需要对FLT3-ITD如何影响AML的细胞生物学进行研究分析。

FLT3酪氨酸激酶受体中的内部串联重复突变(FLT3-ITD),在急性髓性白血病(AML)中的发生率约为25%,并且与不良预后相关。为了更好地针对此类AML亚型,需要对FLT3-ITD如何影响AML的细胞生物学进行研究分析。

在此研究中,作者发现FLT3-ITD的表达增加了AML细胞的基础自噬,并且通过对该受体进行药理学和遗传学抑制后,原代AML样品和细胞系中的自噬均减弱。

针对关键自噬蛋白条件表达的shRNA证明,AML细胞的增殖和异种移植小鼠模型中白血病细胞的存活均离不开自噬。重要的是,当研究者抑制自噬后,体外和体内FLT3抑制剂的抵抗也得到了克服。此外,研究者发现ATF4是FLT3-ITD诱导自噬的基本参与者。 ATF4的细胞水平高度依赖FLT3-ITD的活性,与抑制自噬相似,当下调ATF4后,自噬依赖性的AML细胞增殖受到抑制,小鼠整体存活率也得到改善。

这些结果表明,在表达FLT3突变的患者中以自噬或ATF4为治疗标靶可能是AML潜在的治疗策略。

原始出处:

Heydt Q, Larrue C.et al.Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.376.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048926, encodeId=7297204892661, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 17 03:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557955, encodeId=01b8155e955f6, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558094, encodeId=ec6615580946a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257491, encodeId=aa6425e4912c, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:55:38 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2018-03-17 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048926, encodeId=7297204892661, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 17 03:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557955, encodeId=01b8155e955f6, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558094, encodeId=ec6615580946a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257491, encodeId=aa6425e4912c, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:55:38 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-11-02 appleandpeer
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048926, encodeId=7297204892661, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 17 03:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557955, encodeId=01b8155e955f6, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558094, encodeId=ec6615580946a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257491, encodeId=aa6425e4912c, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:55:38 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-11-02 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048926, encodeId=7297204892661, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 17 03:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557955, encodeId=01b8155e955f6, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558094, encodeId=ec6615580946a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Thu Nov 02 02:18:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257491, encodeId=aa6425e4912c, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:55:38 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-10-31 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

NCCN临床实践指南:急性髓性白血病(2017.V3)

2017年6月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2017年第3版,指南主要内容包括: 指南更新摘要 急性白血病和诊断研究评估(AML-1) APL,诱导治疗(AML-2) APL,巩固后治疗(AML-5) APL,复发治疗(AML-7) AML,治疗反应(年龄<60y)(AML-7) AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8) AML,大剂量阿糖胞

Blood:树突细胞疫苗可以预防或延迟AML缓解期患者复发。

复发是急性髓性白血病(AML)的主要问题,严重影响患者的存活期。现有研究发现,电转WT1-mRNA的树突细胞疫苗可以在一定程度上预防或延缓AML缓解期患者复发急性白血病。

Blood:CDC42调控白血病细胞对称性分裂、抑制其分化。

作为细胞极性的中心调控,CDC42 GTPase的活性在维持正常的造血干细胞和祖细胞(HSC / P)功能上受到精密调控。研究发现,HSC/P转化成急性髓性白血病(AML)与CDC42在白血病细胞中的表达上调和活性增强相关。

Lancet Oncology:Gilteritinib或能有效治疗复发性AML

宾夕法尼亚大学佩雷尔曼医学院和宾夕法尼亚大学艾布拉姆森癌症中心的研究人员表示,一种新药显示出能够靶向急性髓性白血病(AML)最常见和最高级突变之一的能力。研究报告发表在《Lancet Oncology》上。

Leuk Lymphoma:评估G6PD活性有助于识别高风险IFD的AML患者

侵袭性真菌病(IFD)仍然是急性髓性白血病(AML)患者死亡率和发病率的首要原因。2017年11月,发表在《Leuk Lymphoma》的一项研究表明,评估葡萄糖-6-磷酸脱氢酶活性将有助于识别处于较高IFD风险的AML患者,从而设计更强化的监测和治疗策略。

Lancet oncol:Guadecitabine(SCI-100)的不同剂量和用药时间用于首次治疗的急性髓性白血病老年患者的安全性和有效性。

低甲基化药物阿扎胞苷和地西他滨表现出对骨髓增生异常综合征和急性髓性白血病有一定治疗效果,但是完整的肿瘤反应少见而且短暂,或许是因为半衰期短以及对此药物骨髓暴露不佳。Guadecitabine(SGI-110)是二代低甲基化药物,半衰期更长,暴露效果佳。研究人员进行一II期研究,评估SCI-100的两种剂量和时间表用于65岁及以上不适合强烈化疗的首次治疗的急性髓性白血病(AML)患者的安全性和有效性

Baidu
map
Baidu
map
Baidu
map